Triglav Skladi D.O.O. Acquires Shares of 11,000 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Triglav Skladi D.O.O. acquired a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 4th quarter, Holdings Channel.com reports. The fund acquired 11,000 shares of the biotechnology company’s stock, valued at approximately $1,337,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Manchester Capital Management LLC lifted its position in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 156 shares during the period. Newbridge Financial Services Group Inc. purchased a new position in Sarepta Therapeutics during the fourth quarter valued at $36,000. Steward Partners Investment Advisory LLC lifted its position in Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 194 shares during the period. Finally, Smartleaf Asset Management LLC raised its position in shares of Sarepta Therapeutics by 95.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 216 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on SRPT shares. Piper Sandler lowered their price target on Sarepta Therapeutics from $110.00 to $70.00 and set an “overweight” rating for the company in a research report on Wednesday, May 7th. Needham & Company LLC lowered their price target on Sarepta Therapeutics from $183.00 to $125.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Cantor Fitzgerald lowered their price target on Sarepta Therapeutics from $163.00 to $81.00 and set an “overweight” rating for the company in a research report on Wednesday, May 7th. Oppenheimer lowered their price target on Sarepta Therapeutics from $184.00 to $123.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Finally, Morgan Stanley lowered their price target on Sarepta Therapeutics from $182.00 to $113.00 and set an “overweight” rating for the company in a research report on Wednesday, May 7th. Six investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $124.36.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $36.43 on Monday. Sarepta Therapeutics, Inc. has a 52 week low of $34.10 and a 52 week high of $173.25. The firm has a market capitalization of $3.58 billion, a P/E ratio of 29.14 and a beta of 0.85. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a 50-day moving average price of $60.11 and a 200-day moving average price of $97.18.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The business had revenue of $744.86 million for the quarter, compared to analysts’ expectations of $685.75 million. During the same period in the previous year, the company earned $0.73 EPS. Sarepta Therapeutics’s revenue for the quarter was up 80.2% compared to the same quarter last year. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Insider Activity

In other news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. This represents a 8.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.